{"nctId":"NCT01330381","briefTitle":"Prucalopride in Pediatric Subjects With Functional Constipation","startDateStruct":{"date":"2011-04-28","type":"ACTUAL"},"conditions":["Functional Constipation"],"count":215,"armGroups":[{"label":"prucalopride","type":"EXPERIMENTAL","interventionNames":["Drug: prucalopride"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"PEG 4000","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: PEG 4000"]}],"interventions":[{"name":"prucalopride","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"PEG 4000","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n1. Boys and girls, aged ≥ 6 months and \\< 18 years.\n2. Subjects with a confirmed diagnosis of functional constipation as defined by the Rome III criteria.\n\nMain Exclusion Criteria:\n\n1. Children with underlying GI abnormalities and causes for defecation disorders.\n2. Constipation is thought to be drug-induced.\n3. Subjects suffering from secondary causes of chronic constipation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period","description":"Responders are defined as subjects with an average spontaneous defecation frequency is ≥3 times per week AND the average number of fecal incontinence episodes per 2 weeks is ≤ 1 episode (only for subjects after acquisition of toileting skills).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects With Bowel Frequency of 3 or More Spontaneous Bowel Movements (SBM) Per Week in the Last Four Weeks of the Double-Blind Treatment Period","description":"Spontaneous Bowel Movements defined as a bowel movement that is not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"35.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects With Fecal Incontinence Episodes of 1 or Less Per 2 Weeks in the Last Four Weeks of the Double-Blind Treatment Period","description":"Fecal incontinence is a lack of control over defecation, leading to involuntary loss of bowel contents (only for subjects after acquisition of toileting skills).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0","spread":null},{"groupId":"OG001","value":"43.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Retentive Posturing or Excessive Volitional Stool Retention in the Double-Blind Treatment Period","description":"Purposefully avoiding defecation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.82"},{"groupId":"OG001","value":"1.2","spread":"1.71"}]}]}]},{"type":"SECONDARY","title":"Painful Bowel Movements Score in the Double-Blind Treatment Period","description":"Pain was rated on a 6-point scale (0=no hurt, 1=hurts little bit, 2=hurts little more, 3=hurts even more, 4=hurts whole lot, 5=hurts worst) in subjects of 3 years and older. Lower scores represent less pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.25"},{"groupId":"OG001","value":"1.7","spread":"1.34"}]}]}]},{"type":"SECONDARY","title":"Stool Consistency Per SBM Score in Children Without Diapers in the Double-Blind Treatment Period","description":"Measured using the 7-point Bristol scale where 1-2 indicate constipation, 3-4 are ideal stools, and 5-7 tending toward diarrhea.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"0.96"},{"groupId":"OG001","value":"3.6","spread":"1.17"}]}]}]},{"type":"SECONDARY","title":"Stool Consistency Per SBM Score in Children With Diapers in the Double-Blind Treatment Period","description":"Measured on a 4-point scale where 1 is constipation, 2-3 is ideal, and 4 is diarrhea.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.47"},{"groupId":"OG001","value":"2.0","spread":"0.59"}]}]}]},{"type":"SECONDARY","title":"Large Diameter Stools in the Double-Blind Treatment Period","description":"Large diameter stools make defecation more difficult. Small diameter stools are better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.67"},{"groupId":"OG001","value":"1.7","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Abdominal Pain Score in Double-Blind Treatment Period","description":"Pain was rated on a 6-point scale (0=no hurt, 1=hurts little bit, 2=hurts little more, 3=hurts even more, 4=hurts whole lot, 5=hurts worst) in subjects of 3 years and older. Lower scores represent less pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.18"},{"groupId":"OG001","value":"1.1","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Frequency of Toilet Training in the Double-Blind Treatment Period","description":"Only for subjects after acquisition of toileting skills.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"2.47"},{"groupId":"OG001","value":"5.1","spread":"2.47"}]}]}]},{"type":"SECONDARY","title":"Number of Rescue Medications Taken in the Double-Blind Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.25"},{"groupId":"OG001","value":"1.3","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"Time to First SBM in the Double-Blind Treatment Period","description":"After intake of the trial medication on Day 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.00","spread":null},{"groupId":"OG001","value":"99.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of SBM Per Week in the Double-Blind Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"2.35"},{"groupId":"OG001","value":"2.1","spread":"1.74"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Number of SBM Per Week Over the 8 Week Double Blind Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"2.35"},{"groupId":"OG001","value":"1.0","spread":"1.78"}]}]}]},{"type":"SECONDARY","title":"Severity of Constipation Over the Past 2 Weeks for the Final On Treatment Assessment in the Double-Blind Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"24.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"24.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Severity of Constipation Over the Past 2 Weeks for the Final On Treatment Assessment in the Open-Label Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":null},{"groupId":"OG001","value":"46.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of Treatment for Final On Treatment Assessment in Double-Blind Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of Treatment for Final On Treatment Assessment in Open-Label Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"46.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Convenience of Treatment for Final On Treatment Assessment in Open-Label Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"28.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.6","spread":null},{"groupId":"OG001","value":"47.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":106},"commonTop":["Abdominal pain","Headache","Vomiting","Pyrexia","Diarrhea"]}}}